Pyridostigmine Bromide Er (pyridostigmine bromide)

Since pyridostigmine is excreted predominantly by the kidneys, the manufacturer of Mestinon(R) states that lower dosages of pyridostigmine bromide may be required in patients with renal disease. In such patients, the dosage should be titrated carefully to produce the desired effect.

Pyridostigmine bromide is administered orally (as conventional tablets, extended-release tablets, or oral solution) or by IV injection. The drug also has been administered by IM injection, but the manufacturer of the currently available injectable preparation states that the injection is for IV use only.

When used as a neuromuscular reversal agent, pyridostigmine should be administered only by trained clinicians experienced in the use of such agents. Patients must be well ventilated and have a patent airway prior to administration of pyridostigmine and until complete recovery of normal respiration. Continuous monitoring of neuromuscular function is recommended to ensure adequate reversal from the neuromuscular block. To exclude with certainty the possibility of residual paralysis, an objective (quantitative) method of monitoring such as peripheral nerve stimulation should be used in conjunction with other clinical assessments (e.g., observation of skeletal muscle tone, respiratory measurements). Adequate recovery of neuromuscular function generally is defined as a train-of-four (TOF) ratio of 0.9 in addition to the patient's ability to maintain satisfactory ventilation and a patent airway.

When pyridostigmine is administered as conventional dosage forms for the symptomatic treatment of myasthenia gravis, the dosage should be adjusted so that larger doses are taken at times of greatest fatigue (e.g., 30-45 minutes before meals to assist patients who have difficulty eating).

Pyridostigmine oral solution is especially useful for children and patients who have difficulty swallowing, and the solution may be administered through a nasogastric tube, if necessary.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

Few data are available regarding the effects of cholinesterase inhibitors, including pyridostigmine, on the fetus because of the rarity of maternal conditions requiring the use of these drugs during pregnancy. Transient muscular weakness has occurred in 10-20% of neonates whose mothers received anticholinesterase drugs for the treatment of myasthenia gravis, although similar symptoms have also been reported in infants whose mothers were not treated with these drugs. Some experts state that oral pyridostigmine is the first-line treatment of choice for pregnant women with myasthenia gravis. However, anticholinesterase drugs may cause uterine irritability and induce premature labor when given IV to pregnant women near term. Use of pyridostigmine in pregnant women requires that the possible benefits be weighed against the potential risks.

Since it is not known whether pyridostigmine is distributed into milk, the drug should be used with caution in nursing women.

No enhanced messaging available.